A61P 15/08
Drugs for genital or sexual disorders: for gonadal disorders or for enhancing
Official title: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P15/08 (Drugs for genital or sexual disorders: for gonadal disorders or for enhancing) appears on 3,478 US grants and 5,738 published applications in this corpus.
Search patents in A61P- Granted patents
- 3,478
- Published applications
- 5,738
- Assignees
- 1,739
- Inventors
- 9,996
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 9 | 0 |
| 1997 | 8 | 0 |
| 1998 | 13 | 0 |
| 1999 | 20 | 0 |
| 2000 | 35 | 0 |
| 2001 | 44 | 12 |
| 2002 | 60 | 124 |
| 2003 | 78 | 202 |
| 2004 | 68 | 287 |
| 2005 | 70 | 284 |
| 2006 | 126 | 286 |
| 2007 | 117 | 325 |
| 2008 | 143 | 378 |
| 2009 | 166 | 427 |
| 2010 | 227 | 479 |
| 2011 | 221 | 366 |
| 2012 | 262 | 336 |
| 2013 | 276 | 295 |
| 2014 | 271 | 300 |
| 2015 | 250 | 283 |
| 2016 | 179 | 215 |
| 2017 | 159 | 196 |
| 2018 | 142 | 165 |
| 2019 | 108 | 152 |
| 2020 | 105 | 120 |
| 2021 | 97 | 99 |
| 2022 | 56 | 90 |
| 2023 | 44 | 106 |
| 2024 | 39 | 84 |
| 2025 | 44 | 79 |
| 2026 | 36 | 48 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fused polycyclic substituted 5-carboxylic acid thienopyrimidine dione compound and use thereof22 Sep 2026US 12,741,975 B2Cms Research & Development Pte. Ltd.
- Progesterone formulation to trigger ovulation and provide luteal phase support15 Sep 2026US 12,734,179 B2Augusta University Research Institute, Inc.
- Methods and compositions for treatment of low circulating testosterone conditions1 Sep 2026US 12,721,823 B2University of Florida Research Foundation, Inc.
- Inhibitors of human epididymus protein 425 Aug 2026US 12,715,897 B2University of Rochester
- Method of using a needle assisted injection device having reduced trigger force18 Aug 2026US 12,708,710 B2Antares Pharma, Inc.
- Oral formulations of pyrrolidine derivatives24 Sep 2026US 2026/0284006 A1ReproNovo SA
- Composition for improving unidentified complaints, depression, impaired concentration, decreased motivation for socialization and daily activities, autonomic nervous system disorders, pain, control and poor sleep quality associated with menstruation24 Sep 2026US 2026/0284132 A1Tokiwa Phytochemical Co., Ltd.
- Cells expressing parathyroid hormone 1 receptor and uses thereof24 Sep 2026US 2026/0286293 A1Tithon Biotech Inc.
- Dissolvable microneedle patch for large molecule therapeutic delivery17 Sep 2026US 2026/0273253 A1Maman Biomedical Inc.
- Cells expressing parathyroid hormone 1 receptor and uses thereof17 Sep 2026US 2026/0275277 A1Tithon Biotech Inc.
Most cited
By later US patents
- Methods for fabricating polymer-based controlled release devices312US 5,989,463 AAlkermes Controlled Therapeutics, Inc. · 1999
- Water-soluble non-antigenic polymer linkable to biologically active material304US 6,113,906 AEnzon, Inc. · 2000
- Non-antigenic branched polymer conjugates264US 5,919,455 AEnzon, Inc. · 1999
- Pyrazolopyrimidines as therapeutic agents236US 6,921,763 B2Abbott Laboratories · 2005
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006